Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis-Reference-Cited by-同舟云学术

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis

Published:2016-11-02 Issue:1 Volume:161 Page:73-81
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Jankowski Clémentine^ORCID,Guiu S.,Cortet M.,Charon-Barra C.,Desmoulins I.,Lorgis V.,Arnould L.,Fumoleau P.,Coudert B.,Rouzier R.,Coutant C.,Reyal F.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-4040-4.pdf

Reference32 articles.

1. van der Hage JA, van de Velde CJ, Julien JP et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224–4237

2. Schwartz GF, Hortobagyi GN (2004) Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer 100:2512–2532. doi: 10.1002/cncr.20298

3. Sachelarie I, Grossbard ML, Chadha M et al (2006) Primary systemic therapy of breast cancer. Oncologist 11:574–589. doi: 10.1634/theoncologist.11-6-574

4. Gown AM, Goldstein LC, Barry TS et al (2008) High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 21:1271–1277. doi: 10.1038/modpathol.2008.83

5. Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–785. doi: 10.1200/JCO.2007.15.0235

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preoperative systemic inflammation response index: Clinicopathologic predictor of pathological complete response in HER2-positive breast cancer patients receiving neoadjuvant systemic therapy;Journal of the Chinese Medical Association;2023-12-11

2. Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy;Frontiers in Oncology;2021-07-15

3. Factors affecting pathological complete response after neoadjuvant chemotherapy in breast cancer: a single-center experience;Revista da Associação Médica Brasileira;2021-06

4. Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study;Clinical Breast Cancer;2020-12

5. Comparaison des performances prédictives du TEP-TDM et du nomogramme CGFL/Curie pour prédire la réponse histologique complète après chimiothérapie néo-adjuvante des cancers du sein HER2-positifs;Gynécologie Obstétrique Fertilité & Sénologie ;2020-09